Summary of Significant Accounting Policies (Details) (USD $) Share data in Thousands, unless otherwise specified	3 Months Ended			12 Months Ended				1 Months Ended
	Sep. 30, 2014	Mar. 31, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 18, 2013
Revenue Recognition [Abstract]
Milestone Revenue from Fuji		$ 1,000,000
Milestone Revenue from Salix	40,000,000
Accounts Receivable [Abstract]
Allowance for Doubtful Accounts Receivable, Current				7,000	10,000	7,000
Auction Rate Securities [Abstract]
Auction rate securities				2,208,000	0	2,208,000
Decrease in temporary impairment of auction rate securities					192,000
Goodwill and indefinite lived in-process research and development [Abstract]
Goodwill				7,702,000	7,702,000	7,702,000	0
Goodwill, Acquired During Period						7,702,000
Intangible Assets Acquired During Period						32,300,000
Indefinite-Lived Intangible Assets (Excluding Goodwill)				31,360,000	28,700,000	31,360,000	0
Reclassification to finite lived in-process research and development						(21,000)
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	560,000				(2,660,000)	(919,000)
Beginning of significant cash inflows - year					2024	2021
Finite-lived Intangible Assets [Roll Forward]
Finite-Lived Intangible Assets, Net		19,000			19,000	0		0
Reclassification to finite lived in-process research and development						21,000
Amortization of Intangible Assets				(2,000)	(3,000)	(2,000)
Impairment of Intangible Assets, Finite-lived	(16,000)				(16,000)
Finite-Lived Intangible Assets, Net				19,000	0	19,000	0
Finite-Lived Intangible Assets
Onalta Indefinite Lived IPR&D Impairment	560,000				(2,660,000)	(919,000)
Onalta Finite Lived IPR&D Impairment	16,000				16,000
Finite-Lived Intangible Assets, Gross				21,000		21,000
Finite-Lived Intangible Assets, Accumulated Amortization				2,000		2,000
Finite-Lived Intangible Assets, Net, Total				19,000	0	19,000	0
Finite-Lived Intangible Asset, Useful Life						5 years
Amortization of Intangible Assets				2,000	3,000	2,000
Fair Value Measurements [Abstract]
Contingent consideration liability				15,700,000	17,200,000	15,700,000		15,900,000
Period of milestone achievement - Minimum					2018
Period of milestone achievement - Maximum					2026
Beginning of significant cash inflows - year					2024	2021
Discount rate - milestone-based					10.00%
Discount Rate - net sales targets					3.50%
Discount rate increase resulting in impairment of the remaining book value of MIP-1095					0.135%
Probability of success decrease resulting in impairment of the remaining book value of MIP-1095					0.194%
Indefinite lived intangible assets - Discount Rate					13.50%	20.00%
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability					1,500,000	(200,000)	0
Intangible impairment charge					2,676,000	919,000	0
Other current assets				1,943,000	2,515,000	1,943,000
Restricted cash				157,000	157,000	157,000
Other Asset Impairment Charges			347,000
Deferred Lease Liability and Incentive [Abstract]
Deferred lease incentive - current				115,000	115,000	115,000
Total other current liabilities				115,000	115,000	115,000
Deferred lease liability				224,000	336,000	224,000
Deferred lease incentive - noncurrent				690,000	575,000	690,000
Total other liabilities				914,000	911,000	914,000
Income Taxes [Abstract]
Percentage of income tax benefit realization (in hundredths)					50.00%
Computer Equipment [Member]
Estimated useful lives of fixed assets [Abstract]
Estimated useful life					3 years
Furniture and Fixtures [Member]
Estimated useful lives of fixed assets [Abstract]
Estimated useful life					5 years
Leasehold Improvements [Member]
Estimated useful lives of fixed assets [Abstract]
Useful life description					Earlier of life of improvement or lease
Minimum [Member] | Machinery and Equipment [Member]
Estimated useful lives of fixed assets [Abstract]
Estimated useful life					5 years
Minimum [Member] | Leasehold Improvements [Member]
Estimated useful lives of fixed assets [Abstract]
Estimated useful life					6 years 4 months 24 days	8 years 6 months
Maximum [Member] | Machinery and Equipment [Member]
Estimated useful lives of fixed assets [Abstract]
Estimated useful life					7 years
Maximum [Member] | Leasehold Improvements [Member]
Estimated useful lives of fixed assets [Abstract]
Estimated useful life					10 years 9 months 18 days	10 years 9 months 18 days
Auction Rate Securities [Member]
Auction Rate Securities [Abstract]
Auction rate securities				2,208,000		2,208,000
Azedra commercialization [Member]
Goodwill and indefinite lived in-process research and development [Abstract]
Fair Value								4,900,000
Discount rate								15.00%
Beginning of significant cash inflows - year								2017
Fair Value Measurements [Abstract]
Beginning of significant cash inflows - year								2017
MIP - 1404 commercialization [Member]
Goodwill and indefinite lived in-process research and development [Abstract]
Fair Value								23,200,000
Discount rate								18.00%
Beginning of significant cash inflows - year								2017
Fair Value Measurements [Abstract]
Beginning of significant cash inflows - year								2017
MIP-1095 commercialization [Member]
Goodwill and indefinite lived in-process research and development [Abstract]
Fair Value								2,700,000
Discount rate								20.00%
Beginning of significant cash inflows - year								2021
Fair Value Measurements [Abstract]
Beginning of significant cash inflows - year								2021
Onalta [Member]
Goodwill and indefinite lived in-process research and development [Abstract]
Fair Value								1,500,000
Discount rate								15.00%
Beginning of significant cash inflows - year								2014
Fair Value Measurements [Abstract]
Beginning of significant cash inflows - year								2014
Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cash equivalents				60,364,000	112,808,000	60,364,000
Commercial Bank [Member]
Cash and Cash Equivalents [Line Items]
Cash equivalents				5,496,000	6,494,000	5,496,000
Restricted Stock [Member]
Shares of unvested restricted stock outstanding (in shares) [Line Items]
Shares of unvested restricted stock outstanding (in shares)							28
Salix Agreement [Member]
Revenue Recognition [Abstract]
Upfront license fee, received						60,000,000
MedImmune Agreement [Member]
Revenue Recognition [Abstract]
Upfront license fee, received					5,000,000
CytoDyn Agreement [Member]
Revenue Recognition [Abstract]
Upfront license fee, received						3,500,000
Onalta Agreement [Member]
Revenue Recognition [Abstract]
Upfront license fee, received						$ 200,000